Caribou Biosciences Report issue

For profit Phase 1
Founded: Berkeley CA United States (2011)

Organization Overview

First Clinical Trial
2020
NCT04637763
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Caribou Biosciences, Inc.

Active Ingredients

Drugs in Phase 1 Trials (5)

cb-010 (1 trial)

cb-011 (1 trial)

cb-012 (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 5